|
|
Quark Pharmaceutical Inc.
Sector: Biotechnology
Sub-Sector: Pharmaceuticals, Biopharmaceuticals, Biogenerics
Medical Field: Ophthalmology
Est.: 1994
Stage: Clinical
http://www.quarkpharma.com
| QUARK is conducting clinical studies in the areas of acute kidney injury associated with major cardiovascular surgery, delayed graft function in kidney transplantation and non-arteritic anterior ischemic optic neuropathy. In addition, Pfizer acquired an exclusive worldwide license to our lead siRNA, PF-655, and other siRNA molecules inhibiting its target, RTP-801, and we are collaborating with Pfizer in conducting clinical studies for wet age-related macular degeneration and diabetic macular edema. |
|
|
